I think we can be incredibly more nimble in this country. We have the game plan to do it. We have all these companies from around the world—these are global heads of R and D coming to Canada to do this. We're starting a new project with Genome Canada to try to find cures for children with rare diseases, something that's really difficult to do. We're doing it in a pre-competitive manner, sharing all the data, not filing for patents, and industry is funding it. CIHR, Genome Canada, and CFI are all helping.
In an incredible happening in July, six R and D leaders from Tokyo and the United States from some of these companies are coming to Ottawa to talk about doing one drug discovery program without patents, from idea all the way to testing in humans.
I think this has the potential to completely transform the way the world discovers medicines. It needs to be done, and I am confident that Canada can lead. If we do it, we will definitely have more efficient innovation in the discovery system, more medicines more cheaply on the five-year to ten-year horizon. We'll get the research arms of pharma back in our country. They're coming. The head of R and D of Takeda, from Tokyo, is coming here in July. The head of R and D from Glaxo in London is coming here in July. We'll be able to focus this research on the unknown, and it's a way for Canada to lead and not follow and not be under that street light with everybody else.
I'm sorry for not telling you what I was supposed to tell you, but I think that was fun.